Omega Diagnostics on the rise again

Home UK Omega Diagnostics on the rise again
Omega Diagnostics on the rise again

Omega Diagnostics Group PLC (LON:ODX) jumped 13% to 92.25p following the publication of a report by Ulster University on the Abc-19 COVID-19 lateral flow antibody test.

The test, which has been developed by the UK Rapid Test Consortium, was tested against the Roche and Abbott immunoassays to detect SARS-CoV2 antibodies, alongside the EuroImmun IgG SARS-CoV-2 ELISA, across a large cohort of plasma samples from Northern Ireland.

Using a pseudo gold standard the authors of the report concluded that the UK-RTC AbC-19 lateral flow immunoassay shows a sensitivity of 97.70% and specificity of 100%.

2.25pm: Empyrean Energy appoints joint broker; what usually comes next?

Empyrean Energy PLC (LON:EME) shares eased 6.5% to 3.95p after the company appointed First Equity Limited as its joint broker.

The share price reaction is unlikely to be a verdict on Cenkos; it is more likely that investors suspect that the new broker may be coming on board to help an equity issue get away.

1.20pm: Wincanton canters higher after resilient trading performance

Wincanton Plc (LON:WIN), the logistics company, motored 10p (4.7%) higher to 222p after it said trading remains “resilient”.

The Digital and eFulfilment business continues to benefit from increased demand for online retail, while performance and the level of new business wins across the rest of the group has been encouraging.

Its barely more than three weeks since the company raised full-year guidance so it is not surprising it has left that guidance unchanged.

12.15pm: OptiBiotix indirectly buoyed by FDA authorisation

OptiBiotix Health PLC (LON:OPTI) was up 4.6% at 57.5p on news of an investigational new drug authorisation.

A drug development firm has been given the green light to take into human trials a treatment for irritable bowel syndrome (IBS) that contains OptiBiotixs Lactobacillus Plantarum LPLDL probiotic.

The company said Seed Healths investigational new drug application has been approved by the US Food & Drug Administration, which will allow DS-01 to go straight into phase II clinical trials.

11.10am: Pires Investments rises after update on portfolio company

Pires Investments PLC (LON:PIRI) advanced 6.7% to 4.8p after a company in which it has a stake announced a new product related to coronavirus COVID-19.

Pires has a 13.3% interest in Sure Valley Ventures (SVV), a venture capital fund focused on investing in the software technology sector with a specific focus on artificial intelligence, the internet of things and immersive technologies.

SVV itself has within its investment portfolio a company called Ambisense, which has launched a product called AmbiAir, which manages, assesses and predicts the COVID-19 risk in commercial and public buildings.

10.05am: Centamin lowers guidance

Centamin PLC (LON:CEY) lost 18% of its value at 164.6p after it reduced production guidance for the current year.

The change was occasioned by ground movement, which forced an area of the Sukari gold mine to be shut down. The movement was in a localised area of waste material in the Sukari open-pit Stage 4 West wall, the gold miner said in a statement.

Open-pit mining operations in this zone have been halted as a preventative safety measure, Centamin added.

9.00am: Arcontech jumps after bagging new client

Arcontech Group PLC (LON:ARC) surged 13% to 167p after the real-time financial market data specialist announced a new client win.

The fintech firm has signed a new Tier 1 bank client for its Multi-Vendor Contribution System, which enables parties to provide information to numerous outlets simultaneously.

The bank will use the system to provide real-time prices to data aggregator Factset.

Cruises operator Carnival PLC (LON:CCL) was sitting low in the water, down 3% at 940.8p, after it flagged up an imminent business update.

The company has scheduled a conference call with analysts for Thursday, October 8.

Yesterday afternoon, the operator of “floating Petri dishes” said its Carnival Cruise Line business had cancelled cruises from all US home ports except Miami and Port Canaveral for November and December 2020.

Proactive news headlines

Cobra Biologics will manufacture Scancell Holdings PLCs (LON:SCLP) COVID-19 vaccine ready for a phase I clinical trial. The agreement covers the good manufacturing practice (GMP) production of plasmid DNA needed to generate the inoculation against SARS-CoV-2.

A drug development firm has been given the green light to take into human trials a treatment for irritable bowel syndrome (IBS) that contains OptiBiotix Health PLC's (LON:OPTI) Lactobacillus Plantarum LPLDL probiotic. The company said Seed Healths investigational new drug application has been approved by the US Food & Drug Administration, which will allow DS-01 to go straight into phase II clinical trials.

One Media IP Group PLC (LON:OMIP) has now paid the final US$100,000 of the fee for the acquisition of the music catalogue of Philip Wesley. The digital music rights acquirer, publisher and distributor acquired the catalogue of the American composer and solo piano artist a year ago but part of the payment was deferred, as it was dependent on how well the deal panned out.

Falcon Oil & Gas Ltd (Read More – Source

[contf] [contfnew]

Proactiveinvestors

[contfnewc] [contfnewc]